Kohei Fukuoka
Overview
Explore the profile of Kohei Fukuoka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoshida Y, Tanihara T, Hamasaki K, Tsurusaki F, Fukuda T, Adachi S, et al.
Theranostics
. 2025 Jan;
15(2):340-361.
PMID: 39744689
Macrophage phagocytosis plays a role in cancer immunotherapy. The phagocytic activity of macrophages, regulated by circadian clock genes, shows time-dependent variation. Intervening in the circadian clock machinery of macrophages is...
2.
Yoshida Y, Nishikawa N, Fukuoka K, Tsuruta A, Otsuki K, Fukuda T, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684718
Defects in Aryl hydrocarbon receptor nuclear translocator-like 1 (ARNTL), a central component of the circadian clock mechanism, may promote or inhibit the induction of inflammation by monocytes/macrophages, with varying effects...
3.
Kinoshita S, Hara C, Matsumoto Y, Fukuoka K, Nakagawa K, Hokuto D, et al.
Hernia
. 2024 Dec;
29(1):40.
PMID: 39625552
Purpose: The role of abdominal compliance in pneumoperitoneum is not fully understood. This study aimed to clarify the association between abdominal wall stretching tendency and surgical stress in laparoscopic groin...
4.
Fukuoka K, Zhao J, Oshima K, Honda M, Mitani Y, Mori M, et al.
Br J Haematol
. 2024 Oct;
205(6):2519-2522.
PMID: 39463037
No abstract available.
5.
Horiguchi A, Arakawa Y, Mitani Y, Isobe K, Mori M, Fukuoka K, et al.
Pediatr Int
. 2024 Jun;
66(1):e15774.
PMID: 38924603
Background: Regular prophylaxis with activated prothrombin complex concentrates (aPCCs) is effective in adult patients with hemophilia with inhibitors; however, data in children are scarce. Methods: This was a single-center retrospective...
6.
Ikuta K, Fukuoka K, Kimura Y, Nakagaki M, Ohga M, Suyama Y, et al.
J Tissue Viability
. 2024 Jun;
33(3):387-392.
PMID: 38825443
Background: The development of models using deep learning (DL) to assess pressure injuries from wound images has recently gained attention. Creating enough supervised data is important for improving performance but...
7.
Li J, Hamamura K, Yoshida Y, Kawano S, Uchinomiya S, Xie J, et al.
Biochem Biophys Res Commun
. 2024 May;
720:150077.
PMID: 38759303
Hericenone C is one of the most abundant secondary metabolites derived from Hericium erinaceus, under investigation for medicinal properties. Here, we report that Hericenone C inhibits the second phase of...
8.
OHare P, Cooney T, de Blank P, Gutmann D, Kieran M, Milde T, et al.
Neuro Oncol
. 2024 May;
26(8):1357-1366.
PMID: 38743009
Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection is not possible, is one of a chronic disease with periods of...
9.
Yoshida Y, Fukuda T, Tanihara T, Nishikawa N, Iwasa S, Adachi S, et al.
Biochem Biophys Res Commun
. 2024 Mar;
708:149813.
PMID: 38522403
The chemotherapeutic agent tegafur, a prodrug that prolongs the half-life of fluorouracil (5-FU), exerts antitumor effects against various cancers. Since tegafur is metabolized to 5-FU by CYP2A6 in the liver,...
10.
Kubota H, Arakawa Y, Mizushima Y, Irikura T, Watakabe M, Ishikawa T, et al.
Blood Cell Ther
. 2024 Mar;
7(1):1-9.
PMID: 38486829
Introduction: Temcell is a mesenchymal stem cell (MSC) product approved for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in Japan. However, reports regarding Temcell's efficacy in pediatric patients have been scarce, and...